Rapid quantification of astilbin in rat plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study

Abstract

Astilbin is a potential immunosuppressive agent with minor cytotoxicity. Its oral bioavailability is supposed to be rather low and therefore a sensitive analytical method is required for its pharmacokinetic study after oral administration. A simple, sensitive and rapid liquid chromatography-tandem mass spectrometry(LC-MS/MS) method was developed and validated for the determination of astilbin in rat plasma. Plasma samples were subjected to liquid-liquid extraction with ethyl acetate and separated by reversed phase high performance liquid chromatography(HPLC) with methanol-0.01%(volume fraction) formic acid(50:50, volume ratio) as mobile phase. Quantitive determination was achieved on negative LC-MS/MS by a multiple reaction moitoring method with transitions m/z 449.1→150.9(quantifier) and m/z 449.1→284.9(qualifier) for astilbin and m/z 128.9→42.0 for internal standard(IS). A lower limit of quantification(LLOQ) of ng/mL was achieved within a short cycle time of 3.4 min. The method was successfully applied to a pharmacokinetic study involving oral and intravenous administrations of 6 mg/kg astilbin to six rats.

Keywords

Astilbin / Liquid chromatography-tandem mass spectrometry(LC-MS/MS) / Pharmacokinetics / Rat / Plasma

References

[1] Zhang Q F, Cheung H Y, Zeng L B. J. Nat. Med., 2013, 67: 207.

[2] Zhang Q F, Guo Y X, Zheng G, Wang W J. Nat. Prod. Res., 2013, 27: 277.

[3] Li X, Zhang Y F, Yang L, Feng Y, Deng Y H, Liu Y M, Zeng X. Nat. Prod. Commun., 2012, 7: 181.

[4] Zheng Z G, Duan T T, He B, Tang D, Jia X B, Wang R S, Zhu J X, Xu Y H, Zhu Q, Feng L. J. Pharm. Biomed. Anal., 2013, 77: 44.

[5] Chen T, Li J, Cao J, Xu Q, Komatsu K, Namba T. Planta Med., 1999, 65: 56.

[6] Xu Q, Wu F, Cao J, Chen T, Jiang J, Saiki I, Koda A. Eur. J. Pharmacol., 1999, 377: 93.

[7] Cai Y, Chen T, Xu Q. J. Pharm. Pharmacol., 2003, 55: 691.

[8] Cai Y, Chen T, Xu Q. Inflamm. Res., 2003, 52: 334.

[9] Yi H W, Lu X M, Fang F, Wang J, Xu Q. Int. Immunopharmacol., 2008, 8: 1467.

[10] Closa D, Torres M, Hotter G, Bioque G, Leon O S, Gelpi E, Rosello-Catafau J. Prostaglandins Leukot Essent Fatty Acids, 1997, 56: 331.

[11] Wang X D, Meng M X, Gao L B, Liu T, Xu Q, Zeng S. Int. J. Pharm., 2009, 378: 1.

[12] Zhao R Z, Zhao Y, Zhang L Q, Lu C J. Pak. J. Pharm. Sci., 2013, 26: 1.

[13] Yang X H, Li H B, Chen H, Li P, Ye B P. Acta Pharm. Sinica, 2008, 43: 974.

[14] Chen L, Yin Y, Yi H, Xu Q, Chen T. J. Pharm. Biomed. Anal., 2007, 43: 1715.

[15] Tatsis E C, Boeren S, Exarchou V, Troganis A N, Vervoort J, Gerothanassis I P. Phytochemistry, 2007, 68: 383.

[16] Guo J, Xu Q, Chen T. J. Chromatogr. B, 2004, 805: 357.

[17] Liang Y, Xu Q, Kang A, Xie Y, Xie T, Liu L, Hao H, Xie L, Wang G J. J. Chromatogr. B, 2009, 877: 1765.

[18] US FDA, Bioanalytical Method Validation, Rockville, USA, http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070107.pdf

[19] Wang Y W, Wang L, Gu J K, Chen G, Zhong D F, Zhou H. Chin. J. Anal. Chem., 2003, 31: 709.

[20] Zhang Q F, Nie H C, Shangguan X C, Yin Z P, Zheng G D, Chen J G. J. Agric. Food Chem., 2013, 61: 151.

[21] He Y, Liu H, Xie Z, Liao Q, Lai X, Du Z. Drug Dev. Ind. Pharm., 2013.

[22] Mezghrani O, Ke X, Bourkaib N, Xu B H. Pharmazie, 2011, 66: 754.